Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Common Equity (2019 - 2025)

Pulmonx has reported Common Equity over the past 7 years, most recently at $54.1 million for Q4 2025.

  • Quarterly Common Equity fell 36.93% to $54.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.1 million through Dec 2025, down 36.93% year-over-year, with the annual reading at $54.1 million for FY2025, 36.93% down from the prior year.
  • Common Equity was $54.1 million for Q4 2025 at Pulmonx, down from $60.0 million in the prior quarter.
  • Over five years, Common Equity peaked at $216.1 million in Q1 2021 and troughed at $54.1 million in Q4 2025.
  • The 5-year median for Common Equity is $129.8 million (2023), against an average of $133.4 million.
  • Year-over-year, Common Equity surged 211.39% in 2021 and then plummeted 36.93% in 2025.
  • A 5-year view of Common Equity shows it stood at $193.2 million in 2021, then decreased by 20.3% to $154.0 million in 2022, then dropped by 23.18% to $118.3 million in 2023, then fell by 27.47% to $85.8 million in 2024, then crashed by 36.93% to $54.1 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Common Equity are $54.1 million (Q4 2025), $60.0 million (Q3 2025), and $69.1 million (Q2 2025).